Pharming announces positive results of Phase II/III pivotal clinical study of leniolisib for the treatment of activated PI3K delta syndrome
Pharming Group announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).
I look forward to working with Pharming to bring leniolisib to APDS patients and studying it further in younger children, as well as other patient populations that may benefit from this precisely targeted therapy- Dr. Virgil Dalm
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.